Drug profile · INN
refametinib
refametinib is a dual specificity mitogen-activated protein kinase kinase 2 inhibitor.
NMPA: clinical trials
Patents linked 0
Pipeline programs 2
News articles 0
Drug details — refametinib
- Class
- —
- Route
- —
- Patents
- 0
- Programs
- 2
- Data quality
- 0.70
Quick answer
refametinib is a dual specificity mitogen-activated protein kinase kinase 2 inhibitor.
Key facts
INN refametinib
Mechanism Dual specificity mitogen-activated protein kinase kinase 2 inhibitor
Target Dual specificity mitogen-activated protein kinase kinase 1
Mechanism of action
Dual specificity mitogen-activated protein kinase kinase 2 inhibitor
Primary target: Dual specificity mitogen-activated protein kinase kinase 1
Approval history
| Authority | Status | Date |
|---|---|---|
| NMPA | clinical trials | — |
Pipeline programs
Related & competitor drugs
Frequently asked questions
What is refametinib?
refametinib is a dual specificity mitogen-activated protein kinase kinase 2 inhibitor.